Compare Incyte Corporation (INCY) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Quantumscape Corp — how do they compare? Incyte Corporation trades at $120.51 (market cap $24.54B), while Quantumscape Corp trades at $6.31 (market cap $3.90B). The key difference: Incyte Corporation is far larger — about 6.3× Quantumscape Corp's market cap, and Incyte Corporation is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| INCY | QS | |
|---|---|---|
Market Cap | $24.54B | $3.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $18.44 |
52-Week Low | $81.61 | $4.89 |
Enterprise Value | $20.04B | $3.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
QuantumScape (QS) trades at $6.19, up 1.89% today, with a mixed technical outlook showing bullish oscillators but bearish moving averages. The company remains pre-revenue with significant losses, reporting a net income of -$435.05M in 2025 (company filing, 2025). Recent Q2 2026 earnings beat expectations but highlighted ongoing commercialization delays, with solid-state battery targets pushed to 2029 (The Motley Fool, 2026-08-11).
The stock presents high-risk speculation due to zero revenue and persistent cash burn, offset by potential long-term disruption in battery technology. Analyst sentiment is cautious with 73% hold ratings, reflecting skepticism on near-term execution. Key risks include timeline slippage, funding needs, and competitive pressure in the EV supply chain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
